Coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) initially emerged in December 2019 and has subsequently expanded globally, leading to the ongoing pandemic. The extensive spread of various SARS-CoV-2 variants possesses a serious public health threat. An extensive literature search along with deep analysis was performed to describe and evaluate the characteristics of SARS-CoV-2 variants of concern in relation to the effectiveness of the current vaccines and therapeutics. The obtained results showed that several significant mutations have evolved during the COVID-19 pandemic. The developed variants and their various structural mutations can compromise the effectiveness of several vaccines, escape the neutralizing antibodies, and limit the efficiency of available therapeutics. Furthermore, deep analysis of the available data enables the prediction of the future impact of virus mutations on the ongoing pandemic along with the selection of appropriate vaccines and therapeutics.
Get full access to this article
View all access options for this article.
References
1.
AbbinkP, LemckertAAC, EwaldBA. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol, 2007; 81:4654–4663.
2.
AbbottTR, DhamdhereG, LiuY, et al.Development of CRISPR as an antiviral strategy to combat SARS-CoV-2 and influenza. Cell, 2020; 181:865–876.e12.
3.
AbdelnabiR, FooCS, De JongheS, et al.Molnupiravir inhibits replication of the emerging SARS-CoV-2 variants of concern in a Hamster infection model. J Infect Dis, 2021; 224:749–753.
4.
AldersonJ, BatchelorV, O'HanlonM, et al.Overview of approved and upcoming vaccines for SARS-CoV-2: A living review. Oxford Open Immunol, 2021; 2:iqab010-iqab010.
5.
AleemA, SlenkerAK. Monoclonal Antibody Therapy for High-Risk Coronavirus (COVID 19) Patients with Mild to Moderate Disease Presentations. BTI–StatPearls, StatPearls Publishing: Treasure Island FL; 2022.
6.
AliF, KasryA, AminM. The new SARS-CoV-2 strain shows a stronger binding affinity to ACE2 due to N501Y mutant. Med Drug Discov, 2021; 10:100086.
7.
AlmehdiAM, KhoderG, AlchakeeAS, et al.SARS-CoV-2 spike protein: Pathogenesis, vaccines, and potential therapies. Infection, 2021; 49:855–876.
8.
UK-health authority. XE Variant: What to Know About the New Hybrid Strain First Identified in UK. 2022
9.
BangaruS, OzorowskiG, TurnerHL, et al.Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. Science, 2020; 370:1089–1094.
10.
BarouchDH, StephensonKE, SadoffJ, et al.Durable humoral and cellular immune responses 8 months after Ad26.COV2.S vaccination. N Engl J Med, 2021; 385:951–953.
11.
BartonMI, MacgowanSA, KutuzovMA, et al.Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics. Elife, 2021; 10:e70658.
12.
BentonDJ, WrobelAG, XuP, et al.Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. Nature, 2020; 588:327–330.
13.
BianL, GaoF, ZhangJ, et al.Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies. Expert Rev Vaccines, 2021a;20:365–373.
14.
BianL, GaoQ, GaoF, et al.Impact of the Delta variant on vaccine efficacy and response strategies. Expert Rev Vaccines, 2021b;20:1201–1209.
15.
BianchiM, BorsettiA, CiccozziM, et al.SARS-Cov-2 ORF3a: Mutability and function. Int J Biol Macromol, 2021; 170:820–826.
16.
BosR, RuttenL, van der LubbeJEM, et al.Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses. NPJ Vaccines, 2020; 5:91.
17.
BurioniR, TopolEJ. Assessing the human immune response to SARS-CoV-2 variants. Nat Med, 2021; 27:571–572.
CannalireR, CerchiaC, BeccariAR, et al.Targeting SARS-CoV-2 proteases and polymerase for COVID-19 treatment: State of the art and future opportunities. J Med Chem, 2022; 65:2716–2746.
22.
CaoL, LiY, YangS, et al.The adenosine analogue prodrug ATV006 is orally bioavailable and has potent preclinical efficacy against SARS-CoV-2 and its variants. bioRxiv, 2021; 2021:463130.
23.
CaoY, ZhuX, HossenMN, et al.Augmentation of vaccine-induced humoral and cellular immunity by a physical radiofrequency adjuvant. Nat Commun, 2018; 9:3695.
24.
CathcartAL, Havenar-DaughtonC, LemppFA, et al.The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2. bioRxiv, 2021; 2021:434607.
25.
CDC. SARS-CoV-2 Variant Proportions. data.cdc.gov. 2022. Available from: https://data.cdc.gov/Laboratory-Surveillance/SARS-CoV-2-Variant-Proportions/jr58-6ysp/data [Last accessed: January 3, 2023].
26.
CDC COVID-19 Response Team. SARS-CoV-2 B.1.1.529 (Omicron) variant—United States, December 1–8, 2021. MMWR Morb Mortal Wkly Rep, 2021; 70:1731–1734.
27.
CeruttiG, GuoY, ZhouT, et al.Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. Cell Host Microbe, 2021; 29:819–833.e7.
28.
ChakrabortyC, BhattacharyaM, SharmaAR. Present variants of concern and variants of interest of severe acute respiratory syndrome coronavirus 2: Their significant mutations in S-glycoprotein, infectivity, re-infectivity, immune escape and vaccines activity. Rev Med Virol, 2022; 32:e2270.
29.
ChanKK, DoroskyD, SharmaP, et al.Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2. Science, 2020; 369:1261–1265.
ChenJ, WeiG-W. Omicron BA.2 (B.1.1.529.2): High potential to becoming the next dominating variant. Res Sq, 2022;rs.3.rs-1362445. [Epub ahead of print]; doi: 10.21203/rs.3.rs-1362445/v1
32.
CorbettKS, EdwardsD, LeistSR, et al.SARS-CoV-2 mRNA vaccine development enabled by prototype pathogen preparedness. bioRxiv, 2020; 23020:145920.
33.
CoutardB, ValleC, de LamballerieX, et al.The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res, 2020; 176:104742.
34.
DengX, Garcia-KnightMA, KhalidMM, et al.Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation. medRxiv, 2021; 2021:21252647.
35.
DuanL, ZhengQ, ZhangH, et al.The SARS-CoV-2 spike glycoprotein biosynthesis, structure, function, and antigenicity: implications for the design of spike-based vaccine immunogens. Front Immunol, 2020; 11:576622.
36.
DurmazB, AbdulmajedO, DurmazR. Mutations observed in the SARS-CoV-2 spike glycoprotein and their effects in the interaction of virus with ACE-2 receptor. Medeni Med J, 2020; 35:253–260.
37.
EgloffM-P, FerronF, CampanacciV, et al.The severe acute respiratory syndrome-coronavirus replicative protein nsp9 is a single-stranded RNA-binding subunit unique in the RNA virus world. Proc Natl Acad Sci U S A, 2004; 101:3792–3796.
38.
Eli Lilly. Lilly's Neutralizing Antibody Bamlanivimab (LY-CoV555) Receives FDA Emergency Use Authorization for the Treatment of Recently Diagnosed COVID-19. Eli Lilly and Company: Indianapolis, Indiana; 2020.
39.
FalconeM, TiseoG, ValorianiB, et al.Efficacy of bamlanivimab/etesevimab and casirivimab/imdevimab in preventing progression to severe COVID-19 and role of variants of concern. Infect Dis Ther, 2021; 10:2479–2488.
40.
FerréVM, Peiffer-SmadjaN, VisseauxB, et al. Omicron SARS-CoV-2 variant: What we know and what we don't. Anaesth Crit Care Pain Med, 2022; 41:100998.
41.
FischerW, EronJJ, HolmanW, et al.Molnupiravir, an oral antiviral treatment for COVID-19. Sci Transl Med, 2022; 14:eabl7430.
42.
Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Limits Use of Certain Monoclonal Antibodies to Treat COVID-19 Due to the Omicron Variant [Online]; 2022. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-limits-use-certain-monoclonal-antibodies-treat-covid-19-due-omicron#:∼:text=Monoclonal%20antibodies%20are%20laboratory%2Dmade,certain%20variants%20such%20as%20omicron [Last accessed: February 16, 2022].
43.
García de AlcañízJG, López-RodasV, CostasE. Sword of Damocles or choosing well. Population genetics sheds light into the future of the COVID-19 pandemic and SARS-CoV-2 new mutant strains. J Vaccines Vaccin, 2021; 12(1):445.
44.
GengJ, ChenL, YuanY, et al.CD147 antibody specifically and effectively inhibits infection and cytokine storm of SARS-CoV-2 and its variants delta, alpha, beta, and gamma. Signal Transduct Target Ther, 2021; 6:347.
45.
GongSY, ChatterjeeD, RichardJ, et al.Contribution of single mutations to selected SARS-CoV-2 emerging variants spike antigenicity. Virology, 2021; 563:134–145.
46.
GroupRC, HorbyPW, MafhamM, et al.Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. medRxiv, 2021; 2021:21258542.
47.
HammerschmidtSI, BosnjakB, BernhardtG, et al.Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination. Cell Mol Immunol, 2021; 18:2455–2456.
48.
HirotsuY, OmataM. Discovery of a SARS-CoV-2 variant from the P.1 lineage harboring K417T/E484K/N501Y mutations in Kofu, Japan. J Infect, 2021; 82:276–316.
49.
HoffmannM, AroraP, GroßR, et al.SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell, 2021a;184:2384–2393.e12.
50.
HoffmannM, Hofmann-WinklerH, KrügerN, et al.SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination. Cell Rep, 2021b;36:109415.
51.
HoffmannM, Kleine-WeberH, PöhlmannS. A Multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol Cell, 2020a;78:779–784.e5.
52.
HoffmannM, Kleine-WeberH, SchroederS, et al.SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell, 2020b;181:271–280.e8.
HossainG, TangYD, AkterS. et al. Roles of the polybasic furin cleavage site of spike protein in SARS-CoV-2 replication, pathogenesis, and host immune responses and vaccination. J Med Virol, 2022; 94:1815–1820.
55.
HuJ, HeC-L, GaoQ-Z, et al.D614G mutation of SARS-CoV-2 spike protein enhances viral infectivity. Nat Commun, 2020; 11:6013.
56.
HuX, ShrimpJH, GuoH, et al.Discovery of TMPRSS2 inhibitors from virtual screening. ACS Pharmacol Transl Sci, 2021; 4:1124–1135.
57.
HuY, WenJ, TangL, et al.The M protein of SARS-CoV: Basic structural and immunological properties. Genomics Proteomics Bioinformatics, 2003; 1:118–130.
58.
JacksonLA, AndersonEJ, RouphaelNG, et al.An mRNA vaccine against SARS-CoV-2—Preliminary report. N Engl J Med, 2020; 383:1920–1931.
KannanSR, SprattAN, CohenAR, et al.Evolutionary analysis of the Delta and Delta Plus variants of the SARS-CoV-2 viruses. J Autoimmun, 2021; 124:102715.
63.
KaurSP, GuptaV. COVID-19 Vaccine: A comprehensive status report. Virus Res, 2020; 288:198114–198114.
64.
KorberB, FischerWM, GnanakaranS, et al.Tracking changes in SARS-CoV-2 spike: Evidence that D614G increases infectivity of the COVID-19 virus. Cell, 2020; 182:812–827.e19.
65.
KumarS, ÇalışkanDM, JanowskiJ, et al.Beyond vaccines: Clinical status of prospective COVID-19 therapeutics. Front Immunol, 2021; 12:752227.
66.
KumarS, ThambirajaTS, KaruppananK, et al.Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein. J Med Virol, 2022; 94:1641–1649.
67.
KyriakidisNC, López-CortésA, GonzálezEV, et al.SARS-CoV-2 vaccines strategies: A comprehensive review of phase 3 candidates. NPJ Vaccines, 2021; 6:28–28.
68.
LappsW, HogueBG, BrianDA. Sequence analysis of the bovine coronavirus nucleocapsid and matrix protein genes. Virology, 1987; 157:47–57.
69.
LauringAS, HodcroftEB. Genetic variants of SARS-CoV-2—What do they mean?. JAMA, 2021; 325:529–531.
70.
LeeJ, LeeJ, KimHJ, et al.TMPRSS2 and RNA-dependent RNA polymerase are effective targets of therapeutic intervention for treatment of COVID-19 caused by SARS-CoV-2 variants (B.1.1.7 and B.1.351). Microbiol Spectr, 2021; 9:e0047221.
71.
LiD-D, LiQ-H. SARS-CoV-2: Vaccines in the pandemic era. Mil Med Res, 2021; 8:1.
72.
LiM, LouF, FanH. SARS-CoV-2 variant Omicron: Currently the most complete “escapee” from neutralization by antibodies and vaccines. Signal Transduct Target Ther, 2022; 7:28.
73.
LiX-N, HuangY, WangW, et al.Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: A test-negative case-control real-world study. Emerg Microbes Infect, 2021; 10:1751–1759.
74.
LiuY, LiuJ, JohnsonBA, et al.Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant. Cell Rep, 2022; 39:110829.
75.
LuanB, HuynhT. Insights into SARS-CoV-2's mutations for evading human antibodies: Sacrifice and survival. J Med Chem, 2022; 65:2820–2826.
76.
MadhunAS, HaaheimLR, NilsenMV, et al.Intramuscular matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in mice. Vaccine, 2009; 27:7367–7376.
77.
MagnussonSE, AltenburgAF, BengtssonKL, et al.Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice. Immunol Res, 2018; 66:224–233.
78.
MahaseE. Covid-19: What do we know about the delta omicron recombinant variant?. BMJ, 2022; 376:o792.
79.
MajumdarS, SarkarR. Mutational and phylogenetic analyses of the two lineages of the Omicron variant. J Med Virol, 2022; 94:1777–1779.
80.
MansbachRA, ChakrabortyS, NguyenK, et al.The SARS-CoV-2 spike variant D614G favors an open conformational state. Sci Adv, 2021; 7:eabf3671.
81.
Martínez-FloresD, Zepeda-CervantesJ, Cruz-ReséndizA, et al.SARS-CoV-2 vaccines based on the spike glycoprotein and implications of new viral variants. Front Immunol, 2021; 12:701501.
82.
MengB, KempSA, PapaG, et al.Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7. Cell Rep, 2021; 35:109292.
83.
MiljanovicD, MilicevicO, LoncarA, et al.The first molecular characterization of Serbian SARS-CoV-2 isolates from a unique early second wave in Europe. Front Microbiol, 2021; 12:691154.
84.
MittalA, ManjunathK, RanjanRK, et al.COVID-19 pandemic: Insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2. PLoS Pathog, 2020; 16:e1008762.
85.
MohammadiM, ShayestehpourM. Mirzaei H. The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines. Braz J Infect Dis, 2021; 25:101606–101606.
86.
MonteilV, KwonH, PradoP, et al.Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell, 2020; 181:905–913.e7.
87.
MossP. The T cell immune response against SARS-CoV-2. Nat Immunol, 2022; 23:186–193.
88.
MueckschF, WeisblumY, BarnesCO, et al.Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity, 2021; 54:1853–1868.e7.
89.
MurrayCJL, PiotP. The potential future of the COVID-19 pandemic: Will SARS-CoV-2 become a recurrent seasonal infection?. JAMA, 2021; 325:1249–1250.
90.
MuttineniR, R, NB, PuttyK, MarapakalaK, et al.SARS-CoV-2 variants and spike mutations involved in second wave of COVID-19 pandemic in India. Transbound Emerg Dis, 2022; 69:e1721–e1733.
91.
PainterGR, NatchusMG, CohenO, et al.Developing a direct acting, orally available antiviral agent in a pandemic: The evolution of molnupiravir as a potential treatment for COVID-19. Curr Opin Virol, 2021; 50:17–22.
92.
PatelSP, PatelGS, SutharJV. Inside the story about the research and development of COVID-19 vaccines. Clin Exp Vaccine Res, 2021; 10:154–170.
93.
PetersenE, NtoumiF, HuiDS, et al.Emergence of new SARS-CoV-2 Variant of Concern Omicron (B.1.1.529)—Highlights Africa's research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts. Int J Infect Dis, 2022; 114:268–272.
94.
PintoD, ParkYJ, BeltramelloM, et al.Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature, 2020; 583:290–295.
95.
PlanasD, VeyerD, BaidaliukA, et al.Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature, 2021; 596:276–280.
96.
PokhrelS, KraemerBR, BurkholzS. et al. Natural variants in SARS-CoV-2 spike protein pinpoint structural and functional hotspots with implications for prophylaxis and therapeutic strategies. Sci Rep, 2021; 11:13120.
97.
PozzettoB, LegrosV, DjebaliS, et al.Immunogenicity and efficacy of heterologous ChadOx1/BNT162b2 vaccination. Nature, 2021; 600:701–706.
98.
PucciF, RoomanM. Prediction and evolution of the molecular fitness of SARS-CoV-2 variants: Introducing SpikePro. Viruses, 2021; 13:935.
99.
PulliamJR, Van SchalkwykC, GovenderN, et al.Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa. Science, 2022; 376:6593.
100.
RahimiF, Talebi Bezmin AbadiA. The Omicron subvariant BA.2: Birth of a new challenge during the COVID-19 pandemic. Int J Surg, 2022; 99:106261–106261.
101.
RajputZI, HuS-H, XiaoC-W, et al.Adjuvant effects of saponins on animal immune responses. J Zhejiang Univ Sci B, 2007; 8:153–161.
RamanathanM, FergusonID, MiaoW, et al.SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity. Lancet Infect Dis, 2021; 21:1070.
104.
RameshS, GovindarajuluM, PariseRS, et al.Emerging SARS-CoV-2 variants: A review of its mutations, its implications and vaccine efficacy. Vaccines (Basel), 2021; 9:1195.
105.
ReichmuthAM, OberliMA, JaklenecA, et al.mRNA vaccine delivery using lipid nanoparticles. Ther Deliv, 2016; 7:319–334.
106.
ReuschlA-K, ThorneLG, Zuliani-AlvarezL, et al.Host-directed therapies against early-lineage SARS-CoV-2 retain efficacy against B.1.1.7 variant. bioRxiv:, 2021; 2021:427991.
107.
RothenbergerS, WalserM, MalvezziF, et al.Multi-specific DARPin® therapeutics demonstrate very high potency against mutated SARS-CoV-2 variants in vitro. bioRxiv, 2021; 2021:429164.
108.
RuchTR, MachamerCE. The hydrophobic domain of infectious bronchitis virus E protein alters the host secretory pathway and is important for release of infectious virus. J Virol, 2011; 85:675–685.
109.
SaiagE, GoldshmidtH, SprecherE, et al.Immunogenicity of a BNT162b2 vaccine booster in health-care workers. Lancet Microbe, 2021; 12:e650.
110.
SaitoA, IrieT, SuzukiR, et al.Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. Nature, 2022; 602:00–306.
111.
SanchesPRS, Charlie-SilvaI, BrazHLB, et al.Recent advances in SARS-CoV-2 Spike protein and RBD mutations comparison between new variants Alpha (B.1.1.7, United Kingdom), Beta (B.1.351, South Africa), Gamma (P.1, Brazil) and Delta (B.1.617.2, India). J Virus Erad, 2021; 7:100054.
112.
SatarkerS, NampoothiriM. Structural proteins in severe acute respiratory syndrome coronavirus-2. Arch Med Res, 2020; 51:482–491.
SharmaO, SultanAA, DingH, et al.A review of the progress and challenges of developing a vaccine for COVID-19. Front Immunol, 2020; 11:585354.
115.
SinghAK, SinghA, SinghR, et al.Molnupiravir in COVID-19: A systematic review of literaturef. Diabetes Metab Syndr, 2021; 15:102329.
116.
StarrTN, CzudnochowskiN, LiuZ, et al.SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. Nature, 2021a;597:97–102.
117.
StarrTN, GreaneyAJ, DingensAS, et al.Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. Cell Rep Med, 2021b;2:100255.
118.
StosorV, AngaroneMP. Not all monoclonal antibodies for coronavirus disease 2019 are created equal. J Infect Dis, 2021; 224:1275–1277.
119.
StumppMT, BinzHK, AmstutzP. DARPins: A new generation of protein therapeutics. Drug Discov Today, 2008; 13:695–701.
120.
SunD, SangZ, KimYJ, et al.Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes. Nat Commun, 2021; 12(1):4676.
121.
SurjitM, LalSK. The SARS-CoV nucleocapsid protein: A protein with multifarious activities. Infect Genet Evol, 2008; 8:397–405.
122.
SzemielAM, MeritsA, OrtonRJ, et al.In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2. PLoS Pathog, 2021; 17:e1009929.
123.
TakashitaE, KinoshitaN, YamayoshiS, et al.Efficacy of antibodies and antiviral drugs against Covid-19 Omicron variant. N Engl J Med, 2022; 386:995–998.
124.
TangJW, TooveyOTR, HarveyKN, et al.Introduction of the South African SARS-CoV-2 variant 501Y.V2 into the UK. J Infect, 2021; 82:e8–e10.
125.
TangY, SaulJ, NagaratnamN, et al.Construction of gateway-compatible baculovirus expression vectors for high-throughput protein expression and in vivo microcrystal screening. Sci Rep, 2020; 10:13323.
126.
TaoK, TzouPL, NouhinJ, et al.The biological and clinical significance of emerging SARS-CoV-2 variants. Nat Rev Genet, 2021; 22:757–773.
127.
TeoSP. Review of COVID-19 mRNA vaccines: BNT162b2 and mRNA-1273. J Pharm Pract, 2021;8971900211009650. [Epub ahead of print]; doi: 10.1177/08971900211009650
128.
TeohK-T, SiuY-L, ChanW-L, et al.The SARS Coronavirus E protein interacts with PALS1 and alters tight junction formation and epithelial morphogenesis. Mol Biol Cell,, 2010; 21:3838–3852.
129.
TianF, TongB, SunL, et al.N501Y mutation of spike protein in SARS-CoV-2 strengthens its binding to receptor ACE2. Elife, 2021; 10:e69091.
130.
TieccoG, StortiS, Degli AntoniM, et al.Omicron genetic and clinical peculiarities that may overturn SARS-CoV-2 pandemic: A literature review. Int J Mol Sci, 2022; 23:1987.
131.
TorjesenI. Covid-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear. BMJ, 2021; 375:n2943.
132.
TuYF, ChienCS, YarmishynAA, et al.A review of SARS-CoV-2 and the ongoing clinical trials. Int J Mol Sci, 2020; 21:2657.
133.
TuekprakhonA, NutalaiR, Dijokaite-GuraliucA, et al.Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell, 2022; 185:2422–2433.e13.
134.
TzouPL, TaoK, NouhinJ, et al.Coronavirus Antiviral Research Database (CoV-RDB): An online database designed to facilitate comparisons between candidate anti-coronavirus compounds. Viruses, 2020; 12:1006.
135.
Van DoremalenN, LambeT, SpencerA, et al.ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature, 2020; 586:578–582.
136.
VangeelL, ChiuW, De JongheS, et al.Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antiviral Res, 2022; 198:105252.
137.
WallsAC, ParkYJ, TortoriciMA, et al.Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell, 2020; 181:281–292.e6.
WHO. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. WHO: Geneva; 2021.
143.
WibmerCK, AyresF, HermanusT, et al.SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med, 2021; 27:622–625.
144.
WirnsbergerG, MonteilV, EatonB, et al.Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants. EMBO Mol Med, 2022; 4:e15230.
145.
WiseJ. Covid-19: The E484K mutation and the risks it poses. BMJ, 2021; 372:n359.
146.
WrappD, WangN, CorbettKS, et al.Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science, 2020; 367:1260–1263.
147.
WuNC, YuanM, LiuH, et al.An alternative binding mode of IGHV3–53 antibodies to the SARS-CoV-2 receptor binding domain. Cell Rep, 2020; 33:108274.
148.
WuX, WangY, ChengL, et al.Short-term instantaneous prophylaxis and efficient treatment against SARS-CoV-2 in hACE2 mice conferred by an intranasal nanobody (Nb22). Front Immunol, 2021; 13:865401.
149.
XuC, WangY, LiuC, et al.Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM. Sci Adv, 2021; 7:eabe5575.
150.
YeY, HogueBG. Role of the coronavirus E viroporin protein transmembrane domain in virus assembly. J Virol, 2007; 81:3597–3607.
151.
YuF, LauTL-T, FokM, et al.COVID-19 Delta Variants—Current Status and Implications as of August 2021. Precis Clin Med, 2021; 4:287–292.
152.
YuenC-K, LamJ-Y, WongW-M, et al.SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists. Emerg Microbes Infect, 2020; 9:1418–1428.
153.
ZhouD, DejnirattisaiW, SupasaP, et al.Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell, 2021; 184:2348–2361.e6.
154.
ZouJ, XieX, Fontes-GarfiasCR, et al.The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization. NPJ Vaccines, 2021; 6(1):44.
155.
ZoufalyA, PoglitschM, AberleJH, et al.Human recombinant soluble ACE2 in severe COVID-19. Lancet Respir Med, 2020; 8(11):1154–1158.
156.
ZupancicJM, SchardtJS, DesaiAA, et al.Engineered multivalent nanobodies potently and broadly neutralize SARS-CoV-2 variants. Adv Ther (Weinh), 2021; 4(8):2100099.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
